Publication

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Xie, F., Colin, P. & Van Bocxlaer, J., 1-Nov-2017, In : Talanta. 174, p. 171-178 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

    Final publisher's version, 694 KB, PDF-document

DOI

Cisplatin is a first-line chemotherapeutic for the treatment of a wide variety of cancers since its discovery in the 1960s. Although various techniques have been reported for the measurement of total platinum in biological matrices, such as inductively coupled plasma-mass spectrometry and derivatization procedures, a specific, sensitive and robust assay for the quantification of intact cisplatin is still lacking. Therefore, we present a rapid, selective, sensitive, and reliable UHPLC-MS/MS based method for the determination of intact cisplatin in human plasma in support of a Phase II clinical trial. The optimal chromatographic behavior of cisplatin was achieved on a Syncronis HILIC column (50 x 2.1 mm, 1.7 mu m, zwitterionic stationary phase). The retention behavior of cisplatin on this zwitterion-based stationary phase was well described by an adsorptive interaction model. A simple sample preparation based on protein precipitation combined with the removal of phospholipids by HybridSPE-precipitation was developed. The method was proven to be free of a relative matrix effect. The assay was validated within a range of 20 - 10,000 ng/mL using 100 mu L of plasma sample. The intra and inter day precisions were all less than 7.6%, and none of the bias was greater than 13.1%, thus corroborating that the developed method is precise and accurate. As a proof of concept, the assay has been successfully applied to plasma samples obtained from different patients who were enrolled in the Phase II trial and were treated with cisplatin.

Original languageEnglish
Pages (from-to)171-178
Number of pages8
JournalTalanta
Volume174
Publication statusPublished - 1-Nov-2017

    Keywords

  • Cisplatin, UHPLC-MS/MS, HILIC, Matrix effects, HybirdSPE, Plasma, ICP-MS METHOD, POSTCOLUMN DERIVATIZATION, MONOHYDRATED COMPLEX, QUANTITATIVE-DETERMINATION, HYDRATED COMPLEXES, PLATINUM, PERFORMANCE, VALIDATION, BLOOD, PHOSPHOLIPIDS

View graph of relations

ID: 47471453